PMID- 35229254
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20220603
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Print)
IS  - 0925-5710 (Linking)
VI  - 115
IP  - 6
DP  - 2022 Jun
TI  - Bosutinib-induced lung injury: a report of two cases and literature review.
PG  - 902-905
LID - 10.1007/s12185-022-03304-0 [doi]
AB  - The prognosis of patients with chronic myeloid leukemia (CML) has improved 
      dramatically since the development of tyrosine kinase inhibitors (TKIs). Three 
      second-generation TKIs, including bosutinib, are currently approved for treatment 
      of CML, and show a faster and deeper clinical response than imatinib. Common 
      adverse events (AEs) of bosutinib are diarrhea and hepatic toxicity; however, 
      lung complications are rare. Here, we report two cases of bosutinib-induced 
      severe lung injury, along with a literature review. The events of these cases 
      occurred at early time points and severity was extremely high, requiring 
      high-flow oxygen and steroid treatments. Compared to previously reported cases, 
      the prevalence and severity of the damage may vary among different ethnicities. 
      However, bosutinib-induced lung injury can cause life-threatening complications. 
      In conclusion, patients treated with bosutinib should be monitored carefully to 
      mitigate serious drug-induced lung injury.
CI  - (c) 2022. Japanese Society of Hematology.
FAU - Watanabe, Naoki
AU  - Watanabe N
AD  - Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, 
      Bunkyo-ku, Tokyo, 113-8421, Japan.
FAU - Takaku, Tomoiku
AU  - Takaku T
AUID- ORCID: 0000-0002-6493-6225
AD  - Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, 
      Bunkyo-ku, Tokyo, 113-8421, Japan. ttakaku@juntendo.ac.jp.
FAU - Tsukune, Yutaka
AU  - Tsukune Y
AD  - Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, 
      Bunkyo-ku, Tokyo, 113-8421, Japan.
FAU - Yasuda, Hajime
AU  - Yasuda H
AD  - Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, 
      Bunkyo-ku, Tokyo, 113-8421, Japan.
FAU - Ochiai, Tomonori
AU  - Ochiai T
AD  - Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, 
      Bunkyo-ku, Tokyo, 113-8421, Japan.
FAU - Yamada, Kohei
AU  - Yamada K
AD  - Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, 
      Bunkyo-ku, Tokyo, 113-8421, Japan.
FAU - Nakazawa, Hiroki
AU  - Nakazawa H
AD  - Department of Respiratory, Juntendo University School of Medicine, Tokyo, Japan.
FAU - Hotta, Saori
AU  - Hotta S
AD  - Department of Respiratory, Juntendo University School of Medicine, Tokyo, Japan.
FAU - Nishimaki, Takayasu
AU  - Nishimaki T
AD  - Department of Respiratory, Juntendo University School of Medicine, Tokyo, Japan.
FAU - Takagi, Haruhi
AU  - Takagi H
AD  - Department of Respiratory, Juntendo University School of Medicine, Tokyo, Japan.
FAU - Takahashi, Kazuhisa
AU  - Takahashi K
AD  - Department of Respiratory, Juntendo University School of Medicine, Tokyo, Japan.
FAU - Komatsu, Norio
AU  - Komatsu N
AD  - Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, 
      Bunkyo-ku, Tokyo, 113-8421, Japan.
FAU - Ando, Miki
AU  - Ando M
AD  - Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, 
      Bunkyo-ku, Tokyo, 113-8421, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20220228
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Aniline Compounds)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Nitriles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinolines)
RN  - 5018V4AEZ0 (bosutinib)
SB  - IM
MH  - Aniline Compounds/pharmacology
MH  - *Antineoplastic Agents/therapeutic use
MH  - Humans
MH  - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
MH  - *Lung Injury/chemically induced/drug therapy
MH  - Nitriles/therapeutic use
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - *Quinolines/adverse effects
PMC - PMC8884415
OTO - NOTNLM
OT  - Bosutinib
OT  - Chronic myeloid leukemia
OT  - Drug-induced lung injury
OT  - Steroid pulse treatment
OT  - Tyrosine kinase inhibitor
EDAT- 2022/03/02 06:00
MHDA- 2022/06/07 06:00
PMCR- 2022/02/28
CRDT- 2022/03/01 05:59
PHST- 2021/12/02 00:00 [received]
PHST- 2022/01/31 00:00 [accepted]
PHST- 2022/01/31 00:00 [revised]
PHST- 2022/03/02 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
PHST- 2022/03/01 05:59 [entrez]
PHST- 2022/02/28 00:00 [pmc-release]
AID - 10.1007/s12185-022-03304-0 [pii]
AID - 3304 [pii]
AID - 10.1007/s12185-022-03304-0 [doi]
PST - ppublish
SO  - Int J Hematol. 2022 Jun;115(6):902-905. doi: 10.1007/s12185-022-03304-0. Epub 
      2022 Feb 28.